文献速递类风湿关节炎其他结缔组织病

德国炎症性风湿病患者SARS-CoV-2感染国家登记研究(ReCoVery)

National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
PubMed 文献 · RMD Open · 2020-01-01

德国于2020年3月30日启动全国性在线登记,收集炎症性风湿病(IRD)合并SARS-CoV-2感染患者数据。截至2020年4月25日共登记104例,32%住院,6例死亡。该登记系统可快速生成数据,帮助了解IRD患者感染病程及免疫调节治疗的影响。

要点

  • 截至2020年4月25日共登记104例IRD合并SARS-CoV-2感染患者。
  • 32%患者住院,6例死亡,三分之二已康复。
  • 59%有合并症,42%使用生物类改善病情抗风湿药。

核心结论

  • 德国在疫情初期快速建立了IRD患者SARS-CoV-2感染国家登记系统,4周内登记104例。
  • 该登记系统有助于快速了解IRD患者感染病程,重点关注免疫调节治疗的影响。

研究设计与样本

  • 全国性在线问卷登记(www.COVID19-rheuma.de),2020年3月30日启动,获伦理和数据保护批准。
  • 收集IRD合并SARS-CoV-2感染患者的临床和流行病学参数,包括诊断、抗风湿治疗、合并症和感染病程。

主要发现

  • 截至2020年4月25日共报告104例患者(40男、63女、1例其他性别)。
  • 45%诊断为类风湿关节炎,59%有一种或以上合并症,42%接受生物类改善病情抗风湿药治疗。
  • 32%患者住院,三分之二已康复,6例死亡。

临床怎么用

  • 该登记系统可快速生成数据,为医生和IRD患者提供及时信息。
  • 登记数据可服务于疫情期间IRD患者管理指南的制定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany. METHODS: Using an online questionnaire (www.COVID19-rheuma.de), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters-for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection-are documented. RESULTS: Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course. CONCLUSIONS: In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hasseli R, Mueller-Ladner U, Schmeiser T, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020. PMID: 32878994. doi:10.1136/rmdopen-2020-001332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。